Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+/HER2- Advanced Breast Cancer

Oncologist. 2021 Jul;26 Suppl 3(Suppl 3):S5-S6. doi: 10.1002/onco.13864. Epub 2021 Jun 21.

Abstract

With more than 6 years of follow‐up in the phase III PALOMA‐3 trial, the addition of palbociclib to fulvestrant maintained a significant survival benefit compared with fulvestrant alone in patients with HR‐positive, HER2‐negative advanced breast cancer that progressed on prior endocrine therapy.

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Female
  • Fulvestrant* / therapeutic use
  • Humans
  • Piperazines* / therapeutic use
  • Pyridines* / therapeutic use
  • Receptor, ErbB-2 / therapeutic use

Substances

  • Piperazines
  • Pyridines
  • Fulvestrant
  • Receptor, ErbB-2
  • palbociclib